Use of New Oral Anticoagulants/ Direct Oral Anticoagulants in Malignant Patients

Abstract

Vitamin K antagonists are being used in the last five decades as an effective anticoagulant. However, for the past few years, new oral anticoagulants (NOACs) have been introduced as newer anticoagulant agents, which are gradually replacing the previously used vitamin K antagonist. Yet, these agents have not fully replaced the use of warfarin and heparin. NOACs have few advantages over the vitamin K antagonist as they act on a specific factor of coagulation cascade rather than inhibiting the whole vitamin K synthesis. In this article, all the data has been searched electronically on PubMed and PRISMA guidelines were not followed. Instead, we used MOOSE statements and the data searched on PubMed was from articles published in the last five years. A total of 12,269 patients were observed;,out of which 64.19% had active cancer and 35.80% was observed as a control group comprised of both male or female participants. Approximately 61.14% were using NOACs, 42.83% were on warfarin, and 2.72% were on low-molecular-weight heparin (LMWH). The NOACs used in different patients were in the following percentages; edoxaban (6.81%), apixaban (5.28%), dabigatran (10.09%), and rivaroxaban (10.02%). The use of NOACs has been increasing day by day but these agents have not completely replaced the warfarin or heparin, because of some demerits associated with the use of warfarin and some conditions where these drugs should be avoided. All NOACs have either hepatic or renal clearance so the hepatic activity and creatinine clearance rate must be monitored before the start of NOACs. The drug interaction between anticancer drugs and NOACs is still not fully reported. The effects of NOACs in AF and VTE are therapeutically effective, but in oncology patients several other co-factors are also involved with the use of NOACs due to which, it is either contraindicated or in some cases dose adjustment is required. However, very little information has been collected and more investigation must be done in this perspective. Categories: Cardiology, Oncology, Hematology Keywords: new oral anti-coagulants, atrial fibrillation in cancer patients, venousthromboembolisim in cancer patients, cancer assossiated thrombosis, rivaroxiban in cancer patients, apixaban in cancer patients, edoxaban in cancer patients, dabigatrin in cancer patients Open Access Review Article

The clinical significance of preoperative serum fibrinogen levels and platelet counts in patients with gallbladder carcinoma

“…The previous study demonstrated that increased expression of thrombomodulin might reduce the migration of cancer cells by restraining PI3K and Akt [ 20 ]. Furthermore,increasing evidence showed that the anticoagulant drugs, such as warfarin and heparin, have antitumor effects both in vivo and in vitro [ 21 ]. Anticoagulants, especially the low molecular heparin, have a splendid antitumor effect without fatal bleeding and venous thromboembolism [ 22 ].…”

Perfil de interações medicamentosas de Agentes Antineoplásicos Orais (AAOs) dispensados para pacientes oncológicos

“…Essa classe inovadora detém algumas vantagens em relação aos antagonistas da vitamina K, como um dose fixa sem a necessidade de verificação de coagulação rotineira e menor IMs, onde em estudo in vitro os ACODs exibem pouco efeitos nas enzimas-chave da CYP, não afetando parâmetros farmacocinéticos de outros fármacos. Estudos recentes, não mostraram riscos de sangramentos associados ao edoxaban oral em pacientes com câncer de pulmão, mama e ginecológico (Khan, et al, 2020;Mulder, et al, 2020).…”

Antithrombotic strategy in cancer patients comorbid with acute coronary syndrome and atrial fibrillation

“…Many antitumor drugs inhibit and compete with the cytochrome P-4503A4 enzyme (CYP3A4) or permeability glycoprotein transporter (P-gp). Thus, the simultaneous use of antitumor drugs and NOACs may cause drug-drug interactions, which may enhance anticoagulation of NOACs and thereby increase the risk of major bleeding (128)(129)(130). Meanwhile, the 2018 European Heart Rhythm Association Practical Guide also indicated that strong inhibitors of CYP3A4 or P-gp should not be used with NOACs in AF patients (128).…”